Published in:
01-07-2017 | Endocrine Imaging
“Pseudo-progression” in advanced thyroid cancer in response to kinase inhibitor therapy
Authors:
Sina Jasim, Mark A. Nathan, Keith C. Bible
Published in:
Endocrine
|
Issue 1/2017
Login to get access
Excerpt
Lenvatinib is approved for use in patients with radioactive iodine-resistant differentiated thyroid cancer [
1]. Fluorodeoxyglucose (FDG)
-positron emission tomography (PET
) imaging characteristics can be misleading in response to initial therapy; treating providers need to be familiar with the range of therapy-related imaging changes. …